Browsing Tag
Nuvation Bio Inc.
1 post
Nuvation Bio adds FDA Fast Track to safusidenib as Phase 3 enrollment builds
Nuvation Bio has secured FDA Fast Track designation for safusidenib in IDH1-mutant glioma, adding regulatory momentum to a program backed by long-term Phase 2 responses and an expanding Phase 3 strategy.